Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report

Fig. 2

Clinical response to icotinib treatment. a Primary tumor (left and middle) and brain metastasis (right) at baseline before icotinib treatment. b Partial response after 1 month of treatment. c Progressive disease after 8 months of treatment with icotinib. PD, Progressive disease; PR, partial response

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us